CBS 2019
CBSMD教育中心
中 文

DAPT Duration

Abstract

Recommended Article

ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy JACC Guideline Comparison: JACC State-of-the-Art Review Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months versus aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicenter, open-label, randomized superiority trial Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study Safety of six-month dual antiplatelet therapy after second-generation drug-eluting stent implantation: OPTIMA-C Randomised Clinical Trial and OCT Substudy 6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel) Low-Dose Aspirin Discontinuation and Risk of Cardiovascular Events: A Swedish Nationwide, Population-Based Cohort Study Risk of Early Adverse Events After Clopidogrel Discontinuation in Patients Undergoing Short-Term Dual Antiplatelet Therapy: An Individual Participant Data Analysis Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY)
|<<... 2 3 4 5 6 7 8 ...>>|

JOURNAL：CBS2017 Article Link

Make a Voice to the World

CBS2017


Denver - October 29, from 11 to 11:30 a.m., Dr Peter Block gave Prof Shao-Liang Chen from Nanjing First Hospital an in-depth interview in the Colorado Convention Center at TCT2017 (Transcatheter Cardiovascular Therapy conference). Prof Shao-Liang Chen is the initiator of DK Crush-V, which using randomized, prospective, multinational design to evaluate the efficacy and safety of DK crush over provisional side branch stenting for patients with unprotected left main bifurcation lesions.


With the further development of interventional devices , coronary bifurcation lesions remains as the one of the most challenging cardiovascular diseases to be tackled. Varies of treatment strategies need high reliability, high level of evidence before promoted in global clinical practices. With passion and faith for better clinical outcome, Prof Chen and his research team keep working on this issue over ten years, seeking a better treatment strategy  for unprotected left main bifurcation lesions. This time, he share his professional clinical experiences and perspectives with international colleagues about the "Current practice and perspectives on treatment in left main bifurcation in China" at TCT2017.






As the leading event in the fields of left main coronary artery disease and transcatheter valve disease, this year, TCT2017 presents 12 LBCTs and 16 FRIs to cause attention.  The progress of DK-V is one of the most notable results, which will be released on October 30th at 11:40 am, local time (at 1:40 a.m. on November 1, Beijing time).



Important Events at TCT2017





>CBS CBS 2019

> CBS 2019 REGISTRATION

> CBS 2019 PROGRAM

> CBS 2019 CALL FOR SCIENCE

> CBS 2019 SPOTLIGHTS

 CBSMD

> CBSMD WEBSITE REGISTRATION

> EDUCATION CENTER

> RECOMMANDED PAPER

> TOP 10 RESEARCH PAPER

> PRE-READING

CBS 2019 CBS 2019 FACULTY Education Resource CBSMD Scientific Library
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top